This report covers the 2022-23 financial year. It is our fifth annual report on advertising compliance. Reporting on our enforcement and educational activities fosters transparency and accountability.
- Executive summary
- 2022-23 Highlights
- About the advertising framework
- Advertising compliance data and information
- Unapproved therapeutic goods associated with COVID-19
- Unlawful import, advertising and supply of nicotine vaping products
- Compliance across the medicinal cannabis industry
- Unapproved performance and image enhancing products and sport supplements
- Advertising of therapeutic goods used in the cosmetic and beauty industry
- Advertising of unapproved goods on digital platforms
- Individual high-risk cases
- Compliance education
- Restricted and prohibited representations
- Version history